Vimarsana
Biggest News Aggregation in the World

Pharma Gm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Gm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Gm Today - Breaking & Trending Today

Standing to Appeal Post-Grant Proceedings: A Brief Review of Recent Federal Circuit Opinions | Haug Partners LLP - Vimarsana News

Standing to Appeal Post-Grant Proceedings: A Brief Review of Recent Federal Circuit Opinions | Haug Partners LLP

On April 7, 2021, the Federal Circuit decided Apple Inc. v. Qualcomm Inc., where it held that Apple lacked standing to appeal the final written decisions in two inter partes review (“IPR”) proceedings before the U.S. Patent Trial and Appeal Board (“PTAB”). Shortly before that, on March 22, 2021, almost one year after the Federal Circuit issued an earlier standing opinion in Argentum Pharm. LLC v. Novartis Pharm. Corp., 956 F.3d 1374 (Fed. Cir. 2020), the Supreme Court denied a petition for a writ of certiorari by Argentum. The Federal Circuit’s recent decision in Apple and the Su...

Federal Circuit Reaffirms That There Is No 'Reasonable Expectation Of Success' In Trying To Invalidate A Chemical Compound Claim As Obvious | Kilpatrick Townsend & Stockton LLP - Vimarsana News

Federal Circuit Reaffirms That There Is No 'Reasonable Expectation Of Success' In Trying To Invalidate A Chemical Compound Claim As Obvious | Kilpatrick Townsend & Stockton LLP

To embed, copy and paste the code into your website or blog: The Federal Circuit (in an unpublished opinion) recently reaffirmed the difficulty generic challengers face when trying to establish chemical structural obviousness to invalidate a drug compound patent claim. 1 This recent ruling involved Takeda’s U.S. Patent No. 7,807,689 (“the ‘689 Patent”), which claims alogliptin, a uracil-containing dipeptidyl peptidase IV (“DPP-IV”) inhibitor used to treat Type II diabetes. The ‘689 Patent is listed in the Orange Book for Takeda’s anti-diabetes drug products, Nesina ®, Kazano ...